United Kingdom· GB-APID-42350111000001109
Adtralza 300mg/2ml solution for injection pre-filled pens
A tralokinumab product containing tralokinumab, registered in United Kingdom by LEO Pharma. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Tralokinumab is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH07 (tralokinumab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Tralokinumab · ATC D11AH07
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tralokinumab costs, country by country.
Normalised to the WHO defined daily dose (16.1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tralokinumab · price per daily dose (16.1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$34.49
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Tralokinumab
- Manufacturer
- LEO Pharma
- Country
- United Kingdom (GB)
- ATC code
- D11AH07
- ATC class
- Tralokinumab
- Defined daily dose
- 16.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5702191029390
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tralokinumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaADTRALZALEO Pharma A/S, Ballerup
- SpainADTRALZA 150 mg SOLUCION INYECTABLE EN JERINGA PRECARGADALeo Pharma A/S
- BelgiumAdtralza 150 mgLeo Pharma
- IcelandAdtralzaLEO Pharma A/S*
- PolandAdtralzaLEO Pharma A/S
- SwedenAdtralza 150 mg Injektionsvätska, lösning i förfylld sprutaLEO Pharma A/S
- CanadaADTRALZALEO PHARMA INC
- SwitzerlandAdtralza
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Adtralza
- Liechtenstein · Adtralza
- Norway · Adtralza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dafb05b9-7526-4cbd-9cc6-0409412cb954 GET /v1/drugs/dafb05b9-7526-4cbd-9cc6-0409412cb954?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "42350111000001109",
"desc": "Adtralza 300mg/2ml solution for injection pre-filled pens (LEO Pharma)",
"form": "Solution for injection",
"vpid": "42603211000001109",
"source": "dmd",
"vtm_id": "1340113001",
"strength": "150 mg",
"substance": "Tralokinumab",
"ingredient": "Tralokinumab",
"supplier_code": "2269001000001104"
}See everything about tralokinumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.